Jennifer R Rider

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/10984353/publications.pdf

Version: 2024-02-01

52 papers	3,529 citations	172207 29 h-index	182168 51 g-index
53 all docs	53 docs citations	53 times ranked	6209 citing authors

#	Article	IF	Citations
1	Counterfactual mediation analysis in the multistate model framework for surrogate and clinical timeâ€toâ€event outcomes in randomized controlled trials. Pharmaceutical Statistics, 2022, 21, 163-175.	0.7	6
2	Statin Use Is Associated with Lower Risk of PTEN-Null and Lethal Prostate Cancer. Clinical Cancer Research, 2020, 26, 1086-1093.	3.2	35
3	Impact of age at diagnosis of de novo metastatic prostate cancer on survival. Cancer, 2020, 126, 986-993.	2.0	36
4	Socioenvironmental adversity and risk of prostate cancer in non-Hispanic black and white men. Cancer Causes and Control, 2019, 30, 997-1007.	0.8	2
5	Restricted Mean Survival Times to Improve Communication of Evidence from Cancer Randomized Trials and Observational Studies. European Urology, 2019, 76, 137-139.	0.9	21
6	High inducible nitric oxide synthase in prostate tumor epithelium is associated with lethal prostate cancer. Scandinavian Journal of Urology, 2018, 52, 129-133.	0.6	28
7	FOXP3⁺ regulatory T cells in normal prostate tissue, postatrophic hyperplasia, prostatic intraepithelial neoplasia, and tumor histological lesions in men with and without prostate cancer. Prostate, 2018, 78, 40-47.	1.2	41
8	Differential Gene Expression in Prostate Tissue According to Ejaculation Frequency. European Urology, 2018, 74, 545-548.	0.9	5
9	Corpora amylacea in prostatectomy tissue and associations with molecular, histological, and lifestyle factors. Prostate, 2018, 78, 1172-1180.	1.2	17
10	Expression of IGF/insulin receptor in prostate cancer tissue and progression to lethal disease. Carcinogenesis, 2018, 39, 1431-1437.	1.3	35
11	Regular aspirin use and gene expression profiles in prostate cancer patients. Cancer Causes and Control, 2018, 29, 775-784.	0.8	3
12	Perineural Invasion and Risk of Lethal Prostate Cancer. Cancer Epidemiology Biomarkers and Prevention, 2017, 26, 719-726.	1.1	51
13	The ABC model of prostate cancer: A conceptual framework for the design and interpretation of prognostic studies. Cancer, 2017, 123, 1490-1496.	2.0	6
14	Interpathologist concordance in the histological diagnosis of focal prostatic atrophy lesions, acute and chronic prostatitis, PIN, and prostate cancer. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2017, 470, 711-715.	1.4	12
15	Cholesterol uptake and regulation in high-grade and lethal prostate cancers. Carcinogenesis, 2017, 38, 806-811.	1.3	93
16	Gene expression profiling of prostate tissue identifies chromatin regulation as a potential link between obesity and lethal prostate cancer. Cancer, 2017, 123, 4130-4138.	2.0	11
17	A Walking Intervention Among Men With Prostate Cancer: A Pilot Study. Clinical Genitourinary Cancer, 2017, 15, e1021-e1028.	0.9	20
18	Prognostic Utility of a New mRNA Expression Signature of Gleason Score. Clinical Cancer Research, 2017, 23, 81-87.	3.2	58

#	Article	IF	Citations
19	Reply to CÃ©dric Annweiler, Pierre Bigot, and Spyridon N. Karrasâ€™ Letter to the Editor re: Jennifer R. Rider, Kathryn M. Wilson, Jennifer A. Sinnott, Rachel S. Kelly, Lorelei A. Muccia, Edward L. Giovannucci. Ejaculation Frequency and Risk of Prostate Cancer: Updated Results with an Additional Decade of Follow-up. Eur Urol 2016;70:974â€“82. European Urology, 2017, 71, e18.	0.9	0
20	Vascular morphology differentiates prostate cancer mortality risk among men with higher Gleason grade. Cancer Causes and Control, 2016, 27, 1043-1047.	0.8	5
21	The role of tumor metabolism as a driver of prostate cancer progression and lethal disease: results from a nested case-control study. Cancer & Metabolism, 2016, 4, 22.	2.4	26
22	Ejaculation Frequency and Risk of Prostate Cancer: Updated Results with an Additional Decade of Follow-up. European Urology, 2016, 70, 974-982.	0.9	72
23	Reply to Herney AndrÃ©s GarcÃa-Perdomo and Ramiro Manzano Nunez's Letter to the Editor Re: Jennifer R. Rider, Kathryn M. Wilson, Jennifer M. Sinnott, Rachel S. Kelly, Lorelei A. Mucci, Edward L. Giovannucci. Ejaculation Frequency and Risk of Prostate Cancer: Updated Results with an Additional Decade of Follow-up. Eur Urol 2016;70:974â€“82. European Urology, 2016, 70, e156-e157.	0.9	0
24	Pineal Gland Volume Assessed by MRI and Its Correlation with 6-Sulfatoxymelatonin Levels among Older Men. Journal of Biological Rhythms, 2016, 31, 461-469.	1.4	26
25	Cholesterol Metabolism and Prostate Cancer Lethality. Cancer Research, 2016, 76, 4785-4790.	0.4	61
26	Intracellular location of BRCA2 protein expression and prostate cancer progression in the Swedish Watchful Waiting Cohort. Carcinogenesis, 2016, 37, 262-268.	1.3	7
27	Dietary lycopene intake and risk of prostate cancer defined by ERG protein expression. American Journal of Clinical Nutrition, 2016, 103, 851-860.	2.2	65
28	Metformin and prostate cancer mortality: a meta-analysis. Cancer Causes and Control, 2016, 27, 105-113.	0.8	63
29	Sleep Duration and Disruption and Prostate Cancer Risk: a 23-Year Prospective Study. Cancer Epidemiology Biomarkers and Prevention, 2016, 25, 302-308.	1.1	41
30	Germline Variants in Asporin Vary by Race, Modulate the Tumor Microenvironment, and Are Differentially Associated with Metastatic Prostate Cancer. Clinical Cancer Research, 2016, 22, 448-458.	3.2	29
31	The TMPRSS2:ERG fusion and response to androgen deprivation therapy for prostate cancer. Prostate, 2015, 75, 897-906.	1.2	26
32	A Prospective Investigation of PTEN Loss and ERG Expression in Lethal Prostate Cancer. Journal of the National Cancer Institute, 2015, 108, djv346.	3.0	149
33	Urinary Melatonin Levels, Sleep Disruption, and Risk of Prostate Cancer in Elderly Men. European Urology, 2015, 67, 191-194.	0.9	74
34	Circadian clock genes and risk of fatal prostate cancer. Cancer Causes and Control, 2015, 26, 25-33.	0.8	39
35	Molecular differences in transition zone and peripheral zone prostate tumors. Carcinogenesis, 2015, 36, 632-638.	1.3	34
36	Tumor expression of adiponectin receptor 2 and lethal prostate cancer. Carcinogenesis, 2015, 36, 639-647.	1.3	25

#	Article	IF	Citations
37	Cancer Incidence following Expansion of HIV Treatment in Botswana. PLoS ONE, 2015, 10, e0135602.	1.1	71
38	Radical Prostatectomy or Watchful Waiting in Early Prostate Cancer. New England Journal of Medicine, 2014, 370, 932-942.	13.9	825
39	SPINK1 Protein Expression and Prostate Cancer Progression. Clinical Cancer Research, 2014, 20, 4904-4911.	3.2	71
40	Vasectomy and Risk of Aggressive Prostate Cancer: A 24-Year Follow-Up Study. Journal of Clinical Oncology, 2014, 32, 3033-3038.	0.8	46
41	Long-term Outcomes Among Noncuratively Treated Men According to Prostate Cancer Risk Category in a Nationwide, Population-based Study. European Urology, 2013, 63, 88-96.	0.9	146
42	Natural History of Early, Localized Prostate Cancer: A Final Report from Three Decades of Follow-up. European Urology, 2013, 63, 428-435.	0.9	185
43	Prospective study of effect modification by Toll-like receptor 4 variation on the association between Trichomonas vaginalis serostatus and prostate cancer. Cancer Causes and Control, 2013, 24, 175-180.	0.8	10
44	Long-term Distress After Radical Prostatectomy Versus Watchful Waiting in Prostate Cancer: A Longitudinal Study from the Scandinavian Prostate Cancer Group-4 Randomized Clinical Trial. European Urology, 2013, 64, 920-928.	0.9	73
45	Sleep Disruption Among Older Men and Risk of Prostate Cancer. Cancer Epidemiology Biomarkers and Prevention, 2013, 22, 872-879.	1.1	79
46	CD4 helper T cells, CD8 cytotoxic T cells, and FOXP3+ regulatory T cells with respect to lethal prostate cancer. Modern Pathology, 2013, 26, 448-455.	2.9	71
47	Modification of the Association Between Obesity and Lethal Prostate Cancer by TMPRSS2:ERG. Journal of the National Cancer Institute, 2013, 105, 1881-1890.	3.0	80
48	Circadian Disruption, Sleep Loss, and Prostate Cancer Risk: A Systematic Review of Epidemiologic Studies. Cancer Epidemiology Biomarkers and Prevention, 2012, 21, 1002-1011.	1.1	131
49	The TMPRSS2:ERG Rearrangement, ERG Expression, and Prostate Cancer Outcomes: A Cohort Study and Meta-analysis. Cancer Epidemiology Biomarkers and Prevention, 2012, 21, 1497-1509.	1.1	268
50	Temporal Trends in Cause of Death Among Swedish and US Men with Prostate Cancer. Journal of the National Cancer Institute, 2012, 104, 1335-1342.	3.0	126
51	Inflammation, Focal Atrophic Lesions, and Prostatic Intraepithelial Neoplasia with Respect to Risk of Lethal Prostate Cancer. Cancer Epidemiology Biomarkers and Prevention, 2011, 20, 2280-2287.	1.1	68
52	Common Polymorphisms in the Adiponectin and Its Receptor Genes, Adiponectin Levels and the Risk of Prostate Cancer. Cancer Epidemiology Biomarkers and Prevention, 2011, 20, 2618-2627.	1.1	50